Citizens Financial Group Inc RI grew its stake in Amgen, Inc. (NASDAQ:AMGN) by 1.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,057 shares of the medical research company’s stock after purchasing an additional 965 shares during the period. Citizens Financial Group Inc RI’s holdings in Amgen were worth $12,705,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently bought and sold shares of AMGN. BT Investment Management Ltd acquired a new stake in Amgen in the 2nd quarter worth $11,960,000. ProShare Advisors LLC lifted its holdings in shares of Amgen by 12.7% during the 2nd quarter. ProShare Advisors LLC now owns 458,327 shares of the medical research company’s stock worth $78,938,000 after acquiring an additional 51,801 shares during the period. PNC Financial Services Group Inc. lifted its holdings in shares of Amgen by 2.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 2,168,910 shares of the medical research company’s stock worth $373,551,000 after acquiring an additional 45,003 shares during the period. Lingohr & Partner Asset Management GmbH lifted its holdings in shares of Amgen by 71.4% during the 2nd quarter. Lingohr & Partner Asset Management GmbH now owns 8,165 shares of the medical research company’s stock worth $1,340,000 after acquiring an additional 3,400 shares during the period. Finally, Thrivent Financial For Lutherans lifted its holdings in shares of Amgen by 107.1% during the 2nd quarter. Thrivent Financial For Lutherans now owns 118,342 shares of the medical research company’s stock worth $20,382,000 after acquiring an additional 61,212 shares during the period. Institutional investors own 79.53% of the company’s stock.
In related news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $185.62, for a total transaction of $283,070.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 4,575 shares of company stock valued at $838,064 over the last three months. 0.19% of the stock is currently owned by insiders.
A number of equities analysts have recently commented on the stock. Mizuho raised their price objective on shares of Amgen from $192.00 to $200.00 and gave the stock a “buy” rating in a report on Monday, February 12th. Leerink Swann reaffirmed a “market perform” rating on shares of Amgen in a report on Friday, February 2nd. Morgan Stanley reduced their price objective on shares of Amgen from $204.00 to $196.00 and set an “overweight” rating for the company in a report on Friday, February 2nd. BMO Capital Markets raised their price objective on shares of Amgen from $192.00 to $202.00 and gave the stock a “market perform” rating in a report on Friday, February 2nd. Finally, JPMorgan Chase reaffirmed a “hold” rating and set a $191.00 price objective on shares of Amgen in a report on Sunday, February 4th. Two analysts have rated the stock with a sell rating, fourteen have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $190.57.
Shares of AMGN stock opened at $168.14 on Friday. Amgen, Inc. has a 12-month low of $152.16 and a 12-month high of $201.23. The stock has a market cap of $125,031.95, a P/E ratio of 13.37, a PEG ratio of 2.13 and a beta of 1.36. The company has a quick ratio of 5.17, a current ratio of 5.49 and a debt-to-equity ratio of 1.35.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The firm had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.84 billion. During the same period in the prior year, the business earned $2.89 earnings per share. The company’s revenue for the quarter was down 2.7% on a year-over-year basis. equities research analysts expect that Amgen, Inc. will post 13.25 EPS for the current fiscal year.
Amgen declared that its Board of Directors has initiated a stock repurchase plan on Thursday, February 1st that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the medical research company to purchase shares of its stock through open market purchases. Shares buyback plans are often a sign that the company’s leadership believes its stock is undervalued.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be issued a dividend of $1.32 per share. This represents a $5.28 annualized dividend and a yield of 3.14%. The ex-dividend date of this dividend is Wednesday, May 16th. Amgen’s dividend payout ratio is currently 41.97%.
TRADEMARK VIOLATION WARNING: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/amgen-inc-amgn-shares-bought-by-citizens-financial-group-inc-ri.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.